NCT04476979View on ClinicalTrials.gov

Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19

PHASE2CompletedINTERVENTIONAL
Enrollment

453

Participants

Timeline

Start Date

July 16, 2020

Primary Completion Date

June 1, 2021

Study Completion Date

August 11, 2021

Conditions
Coronavirus InfectionSARS (Severe Acute Respiratory Syndrome)Virus DiseasesCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsRespiratory Tract InfectionsRespiratory Tract Disease
Interventions
DRUG

Tocilizumab

Tocilizumab 8mg/kg D1 and if no response (No decrease of oxygen requirement) a second fixed dose of 400mg wil be administered at D3

DRUG

Dexamethasone

Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)

Trial Locations (1)

Unknown

CH Andrée Rosemon, Cayenne

All Listed Sponsors
collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04476979 - Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19 | Biotech Hunter | Biotech Hunter